Recent Updates
Recently added Catalysts
PEPG Negative Sentiment Score: 25/100

PEPGEN ALERT: Bragar Eagel & Squire, P.C. Urges Investors in PepGen, Inc. (PEPG) to Inquire About Their Rights in Class Action Lawsuit

Key Takeaway: Bragar Eagel & Squire, P.C. has announced a class action lawsuit against PepGen, Inc. on behalf of investors who acquired securities between March 7, 2024, and March 3, 2025. The lawsuit alleges that the company made false and misleading statements regarding its drug PGN-EDO51 and the CONNECT2 study, suggesting that these claims misrepresented the effectiveness and safety of the drug. Investors are urged to contact the law firm to discuss their rights and options regarding the lawsuit.

Market Sentiment Analysis

CONCERNS & RISKS

  • A class action lawsuit has been filed against PepGen, alleging they made materially false and misleading statements.
  • The complaint claims PGN-EDO51 was less effective and safe than represented, potentially impacting the company's credibility.
  • The CONNECT2 study is alleged to be deficient for FDA approval and may be halted due to previous misleading claims.

Full Press Release Details

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In PepGen (PEPG) To Contact Him Directly To Discuss Their Options
If you purchased or acquired securities in PepGen between March 7, 2024 and March 3, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648.
NEW YORK, July 16, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against PepGen, Inc. (“PepGen” or the “Company”) (NASDAQ: PEPG) in the United States District Court for the Eastern District of New York on behalf of all persons and entities who purchased or otherwise acquired PepGen securities between March 7, 2024 and March 3, 2025, both dates inclusive (the “Class Period”). Investors have until August 8, 2025 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
Click here to participate in the action.
The complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) PGN-EDO51 was less effective and safe than Defendants had led investors to believe; (ii) the CONNECT2 study was dangerous or otherwise deficient for purposes of U.S. Food and Drug Administration ("FDA") approval; (iii) as a result of all the foregoing, PepGen was likely to halt the CONNECT2 study, and PGN-EDO51's clinical, regulatory, and commercial prospects were overstated; and (iv) as a result, Defendants' public statements were materially false and misleading at all relevant times.
If you purchased or otherwise acquired PepGen shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at investigations@bespc.com, telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.
Follow us for updates on LinkedIn, X, and Facebook, and keep up with other news by following Brandon Walker, Esq. on LinkedIn and X.
Contact Information:
Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Marion Passmore, Esq.

Tags

Bragar Eagel & Squire

Frequently Asked Questions

What is the class action lawsuit against PepGen about?

The lawsuit claims PepGen made false statements about its business and prospects during the Class Period.

Who should contact Bragar Eagel & Squire?

Investors who acquired PepGen securities between March 7, 2024, and March 3, 2025, should reach out.

When is the deadline to apply as lead plaintiff?

The deadline to apply to be lead plaintiff is August 8, 2025.

What are the claims regarding PGN-EDO51?

Claims allege PGN-EDO51 was less safe and effective than PepGen indicated to investors.

Is there a cost to discuss my legal rights?

No, there is no cost or obligation to discuss your rights with the firm.

Last updated: Jul 16, 2025